HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
45
Stocks News & Analysis
stocks
Signs of a turnaround for undervalued ASX share
stocks
Australia has the highest dividend yields in the world, so why the endless chase for even higher yields?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,825.10 | 20.90 | 0.24% |
CAC 40 | 8,178.54 | 14.43 | 0.18% |
DAX 40 | 22,513.42 | 98.60 | -0.44% |
Dow JONES (US) | 44,546.08 | 165.35 | -0.37% |
FTSE 100 | 8,732.46 | 32.26 | -0.37% |
HKSE | 22,620.33 | 805.96 | 3.69% |
NASDAQ | 20,026.77 | 81.13 | 0.41% |
Nikkei 225 | 39,149.43 | 312.04 | -0.79% |
NZX 50 Index | 12,989.18 | 83.20 | 0.64% |
S&P 500 | 6,114.63 | 0.44 | -0.01% |
S&P/ASX 200 | 8,555.80 | 15.80 | 0.19% |
SSE Composite Index | 3,346.72 | 14.24 | 0.43% |